Our mission is to form partnerships with forward thinking companies in healthcare, defence, business and hospitality, to protect society against pandemics and biological attack.

Managing Director and Airshield's inventor Nigel Shepherd first started experimenting with ways to prevent the transmission of the virus in the air by capturing the aerosols through an air intake in 2020 and has been working on ever improving prototypes since. With a strong engineering and management background, Nigel has always applied validated engineering principles to achieve high quality and long-lasting value and this remains his ethos in the development and commercialisation of Airshield.

Director Jeremy Cummin has been involved in healthcare systems for some 40 years with several start-ups and disposals to his credit. He has consulted to major companies in the healthcare and pharmaceutical industries and has acted for several central government departments.
His experience is varied and includes a medical software business specialising in oncology and palliative care, an early-stage health informatics consultancy and an initiative bringing together digital health stakeholders to focus on collaborative volume business development.
Jeremy is a Member of the Royal Society of Medicine

Professor Philippe B. Wilson is a human and animal medical scientist at the interface of prevention, diagnostics and health innovation. He holds several public and private roles including Expert Scientific Committee appointments at Defra, DHSC and the FSA; Chair, Board and NED roles in the private sector, and a charity Trustee. He is a Fellow of the Royal Society of Medicine, Royal Society of Biology and Linnean Society of London.

Airshield Limited owns the patented technology (UK patent GB 2597968) that makes Airshield unique.
The product name Airshield® has been registered as a trademark in respect of classes 11 and 20 under UK00003594231 with effect from 11/02/21.